Introduction
============

Oral cancer is responsible for 200,000--350,000 cancer-associated fatalities per year worldwide and is thus ranked sixth with regard to the cause of mortality due to tumors ([@b1-ol-0-0-3933],[@b2-ol-0-0-3933]).

Beside the time of diagnosis and the consequent size of the tumor ([@b3-ol-0-0-3933]), the presence of lymph node metastasis in the neck is the most important prognostic indicator ([@b4-ol-0-0-3933],[@b5-ol-0-0-3933]). Oral SCC is disseminated preferentially by the lymphatic system and mainly the cervical lymph nodes at levels I and II are affected ([@b6-ol-0-0-3933]--[@b8-ol-0-0-3933]). The high incidence of occult cervical lymph node metastases of \~25% in N0 cases in the clinic underscores the clinical significance and the resulting therapeutic difficulties ([@b9-ol-0-0-3933],[@b10-ol-0-0-3933]).

The commonly used staging procedures often cannot predict the absence of CM. Clinical and radiological examination have approximate false-negative and false-positive rates of 30% in the determination of CM ([@b11-ol-0-0-3933]). The most precise method and the gold standard for the correct N-staging is the histopathological examination of the surgical specimen following elective neck dissection (END) ([@b12-ol-0-0-3933]).

The management of the clinically and radiologically negative neck, particularly in patients with early oral SCC, remains a matter of debate, although the majority of centers favor END for staging of the neck and the removal of occult disease ([@b11-ol-0-0-3933]).

In the modern surgical treatment of melanoma or breast cancer, the presence of regional lymph node metastases is evaluated by the identification and examination of the sentinel lymph node (SLN). Radiolabeled colloid solution is injected around the primary tumor, which drains to the next lymph nodes and predominantly to the SLN, which may contain metastatic deposits of the primary tumor. The combination of pre-operative lymphoscintigraphy and the intraoperative detection of the SLN with a γ-probe allows the radioactive tracer in the lymph nodes to be precisely located during the surgery ([@b11-ol-0-0-3933],[@b13-ol-0-0-3933]).

In the past decade, the SLN-technique has been increasingly used for other malignancies, including head and neck carcinomas. Technical developments and a gain in experience have led to a wider use of SNB, even in the complex lymphatic system of the head and neck region ([@b14-ol-0-0-3933]). Multiple small patient series have been published evaluating the application of SLN biopsy for head and neck cancers, with a sensitivity of at least 75% for the identification of CM ([Table I](#tI-ol-0-0-3933){ref-type="table"}) ([@b11-ol-0-0-3933],[@b15-ol-0-0-3933],[@b16-ol-0-0-3933]). But the majority of these studies included higher stage SCC and did not focus on a specific region and a clinical N0 neck.

The aim of the present study was to analyze and evaluate the applicability of the SLN concept for T1/T2 SCC of the tongue with a clinical N0 situation.

Patients and methods
====================

### Patients

Between 2010 and 2012, 10 patients with SCC of the tongue were selected from the Department of Oral and Maxillofacial of the University Medical Center (Johannes Gutenberg-University of Mainz, Mainz, Germany) to take part in the study. The criteria for inclusion were: SCC of the tongue, a tumor size \<T3 and a clinical N0 situation. All tumors were classified and staged according to the 2003 tumor-node-metastasis (TNM) staging system of the Union for International Cancer Control, and special attention was paid to the CM ([@b17-ol-0-0-3933]).

The study protocol was approved by the internal institutional review board and informed consent was obtained from all the patients involved in the study. Computed tomography and ultrasonography of the head and neck region were performed on all patients prior to the treatment.

### Treatment

All patients received peritumorous injections of technetium-99m-labeled colloidal human serum albumin (0.2 ml; 50 MBq) in an attempt to completely surround the tumor in its deep and lateral aspects. Injection was performed 1 day prior to surgery. The pre-operative lymphoscintigraphy was performed 30 min after the injection. Static images were accomplished in lateral and antero-posterior projections, and the radioactive lymph nodes were marked on the skin and controlled by B-mode sonography.

Beside the resection of the tongue tumor, all patients received an END at levels I--III. Using a hand-held γ-probe (Gamma Finder® II, World Of Medicine USA, Inc., Orlando, Florida, USA), the SLN was identified *in vivo* and dissected separately. Next, the remaining neck was re-evaluated for the absence of radioactivity. All lymph nodes with radioactivity were dissected and considered as SLNs. Afterwards, the proposed END was performed. The SLNs and all neck specimens from the subsequent END were sent for histopathological examination.

Results
=======

The cohort consisted of 5 (50%) female and 5 (50%) male patients, with an average age of 52 years and a range of 21--82 years (female: Mean, 62 years; range, 33--82 years; male: Mean, 42 years; range, 21--69 years). The majority of the patients (70%) showed a risk profile regarding smoking and alcohol consumption ([Table I](#tI-ol-0-0-3933){ref-type="table"}).

SCC was evenly spread in the tongue without a preference for a side, however, 70% was located in the front and middle section of the tongue ([Fig. 1](#f1-ol-0-0-3933){ref-type="fig"}).

The pathological TNM stage of the patients is shown in [Table II](#tII-ol-0-0-3933){ref-type="table"}; 80% of the patients presented with a T1 tumor and 20% with a T2 tumor. No distant metastases were detected following primary staging. The majority of the patients (90%) presented with a tumor of grade G1-G2.

In all patients, SLN could be detected intraoperatively. On average, 2.4 SLNs per patient were found. [Fig. 2](#f2-ol-0-0-3933){ref-type="fig"} shows the distribution of SLNs and CMs at the neck level. A total of 2 SLNs were found in 7 patients, 3 SLNs in 2 patients and 1 SLN in 1 patient were detected. In 7 cases, the SLNs and the residual neck dissection were negative for cervical lymph node metastasis.

In total, 30% (n=3) of the patients exhibited lymph node metastases, which were detected by the SLN biopsy, without further CM in the other neck nodes. One patient exhibited skip metastasis; the patient presented with a CM in a SLN at level IV, which had bypassed the common upper neck level I--III.

Additional CMs were developed in 1 patient after 10 months in the contralateral neck, with lung metastasis after 18 months.

The median follow-up time for the patients was 32 months (range, 8--39 months). During the follow-up, none of the other 9 patients experienced local or cervical recurrence.

If the case with the contralateral CM recurrence after 10 months is defined as a false-negative result, then the sensitivity and specificity of the SLN biopsy in the patient group were 75% (3/4 patients with CM were detected) and 100% (6/6 patient without CN were detected), respectively, and the false negative rate was 25%.

Discussion
==========

The demographic data of the present SCC patients, with a mean age of 52 years and the high presence of risk factors, are comparable with the international literature ([@b15-ol-0-0-3933]--[@b20-ol-0-0-3933]). SCC was evenly spread in the tongue and was identical to the distribution pattern in the literature ([@b21-ol-0-0-3933]).

The management of patients with early oral SCC with a clinically negative neck remains controversial. The majority of clinics prefer the END instead of a wait-and-see strategy due to the high rate of occult metastases. However, 70--80% of this patient group are ultimately pN0 and are theoretically overtreated with a selective neck dissection (SND) ([@b22-ol-0-0-3933],[@b23-ol-0-0-3933]). Although an SND is less invasive than a modified radical dissection, measurable morbidity does exist, including shoulder dysfunction, contour changes, pain and lower lip paresis ([@b24-ol-0-0-3933]--[@b27-ol-0-0-3933]). Although the SND has proven reliability and worldwide acceptance, it is an extended surgery compared with the SLN biopsy, meaning a longer surgical time, higher costs and greater morbidity. Functional outcome and post-operative complications following an SLN biopsy are also significantly better than after an SND ([@b28-ol-0-0-3933],[@b29-ol-0-0-3933]).

The concept of an SLN biopsy provides the possibility of accurate pathological cervical node staging, whilst minimizing the invasiveness of the procedure and its associated morbidity. In addition, pre-operative lymphoscintigraphy and intraoperative detection with a hand-held γ-probe have the additional advantage of identifying aberrant drainage pathways ([@b22-ol-0-0-3933],[@b23-ol-0-0-3933]). In the present study, a contralateral SLN could be detected in 1 patient and a CM was found at level IV, which had bypassed the common upper neck level I--III (skip metastasis).

The SLN biopsy has the benefit of concentrating only on the relevant nodes for pathological examination. This selection allows a more in-depth evaluation of the small number of sentinel nodes, using step serial sections and immunohistochemistry ([@b22-ol-0-0-3933],[@b30-ol-0-0-3933],[@b31-ol-0-0-3933]). However, if there are multiple SLNS at different levels, the number of SLNs that should be removed for the examination remains unknown. The majority of studies recommend the removal of at least 2--3 SLNs to reduce the possibility of false-negative results ([@b32-ol-0-0-3933]--[@b34-ol-0-0-3933]). In the present study, an average of 2.4 SLNs were detected per patient.

There are a number of studies focusing on the use of SLN in SCC ([Table III](#tIII-ol-0-0-3933){ref-type="table"}) ([@b11-ol-0-0-3933],[@b15-ol-0-0-3933],[@b16-ol-0-0-3933],[@b26-ol-0-0-3933],[@b33-ol-0-0-3933],[@b36-ol-0-0-3933],[@b38-ol-0-0-3933]--[@b44-ol-0-0-3933]). But only few studies do have a homogenous clientele with only small tumors and a clinical N0 neck in which the SLN is of importance. In addition the majority of these studies did not focus on a specific region (oral cavity vs. oropharynx). The sensitivity of the SLN biopsy for head and neck cancer varies in the literature between 75 and 100%.

The sensitivity of the SLN biopsy for head and neck cancer varies in the literature between 75 and 100%. This has to be compared with the rate of regional recurrence after SND, which is recorded as between 6--30% in the literature ([@b35-ol-0-0-3933]--[@b37-ol-0-0-3933]). In the present patient group, the sensitivity of the SLN biopsy was 75% when defining the contralateral CM recurrence after 10 months in 1 patient as a false-negative result.

Although further studies are necessary to confirm the results, patients with cN0 and early-stage oral SCC may benefit from an SLN biopsy by avoiding the morbidity of a neck dissection.

![Classification and distribution of the primary tumor location.](ol-11-01-0600-g00){#f1-ol-0-0-3933}

![Distribution of the sentinel lymph nodes (SLNs) detected during the surgery (blue) and distribution of the cervical metastases following pathological examination according to the neck level (red).](ol-11-01-0600-g01){#f2-ol-0-0-3933}

###### 

Epidemiological and clinical data.

  Patient   Gender   Age, years   Risk factors   No. of SLNs detected during surgery   No. of CMs   Follow-up time, months   Relapse
  --------- -------- ------------ -------------- ------------------------------------- ------------ ------------------------ -----------------
    1       Male     21           No             2                                     0            33                       No
    2       Male     28           Yes            2                                     0            39                       No
    3       Male     32           No             4                                     1            18                       After 10 months
    4       Female   33           Yes            2                                     0            22                       No
    5       Female   59           Yes            2                                     1            28                       No
    6       Male     62           Yes            3                                     2            40                       No
    7       Female   63           No             2                                     0            38                       No
    8       Male     69           Yes            2                                     0            40                       No
    9       Female   75           Yes            3                                     0            10                       No
  10        Female   82           Yes            2                                     0            34                       No

SLN, sentinel lymph node; CM, cervical metastases.

###### 

pTNM classification following surgical therapy.

  pTNM stage   Patients, n (%)
  ------------ -----------------
  T-Stage      
    pT1        8 (80)
    pT2        2 (20)
  N-stage      
    pN0        7 (70)
    pN1        2 (20)
    pN2        1 (10)
  M-stage      
    cM0        10 (100)
  Grade        
    G1         4 (40)
    G2         5 (50)
    G3         1 (10)

pTNM, pathological tumor-node-metastasis.

###### 

Published sensitivity rates for SLN biopsy.

  First author (ref.)                     Year   No. of patients with oral SCC/no. of patients   Cancer                 T-Stage   No. of detected CM by SLN/no. of all CM   Sensitivity, %
  --------------------------------------- ------ ----------------------------------------------- ---------------------- --------- ----------------------------------------- ----------------
  Hyde *et al* ([@b38-ol-0-0-3933])       2003   19/19                                           Oral cancer            1--4      3/4                                         75
  Gallegos *et al* ([@b33-ol-0-0-3933])   2005   48/48                                           Oral cancer            1--2      13/17                                       77
  Frerich *et al* ([@b39-ol-0-0-3933])    2007   28/40                                           Oropharyngeal cancer   1--2      8/10                                        80
  Chone *et al* ([@b11-ol-0-0-3933])      2008   24/35                                           Oropharyngeal cancer   1--3      9/11                                        82
  Werner *et al* ([@b30-ol-0-0-3933])     2004   11/90                                           Oropharyngeal cancer   1--3      20/23                                       87
  Civantos *et al* ([@b23-ol-0-0-3933])   2010   140/140                                         Oral cancer            1--2      34/40                                       90
  Tschopp *et al* ([@b40-ol-0-0-3933])    2005   25/31                                           Oropharyngeal cancer   1--3      14/15                                       93
  Shoaib *et al* ([@b41-ol-0-0-3933])     2001   37/37                                           Oral cancer            1--4      16/17                                       94
  Ionna *et al* ([@b42-ol-0-0-3933])      2002   40/40                                           Oral cancer            1--2      4/4                                       100
  Höft *et al* ([@b43-ol-0-0-3933])       2004   22/50                                           Oropharyngeal cancer   1--4      12/12                                     100
  Bilde *et al* ([@b44-ol-0-0-3933])      2008   51/51                                           Oral cancer            1--2      11/11                                     100
  Current study                           2015   10/10                                           Oral cancer            1--2      4/5                                         80

SLN, sentinel lymph node; CM, cervical metastases; T, tumor.
